Medicure Inc.

Medicure Inc.

March 07, 2005 09:17 ET

Medicure Unveils Enhanced Website And New Domain Name


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: MEDICURE INC.

TSX SYMBOL: MPH
AMEX SYMBOL: MCU

MARCH 7, 2005 - 09:17 ET

Medicure Unveils Enhanced Website And New Domain Name

WINNIPEG, MANITOBA--(CCNMatthews - March 7, 2005) - Medicure Inc.
(TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development
company, is pleased to announce the launch of its new corporate website
under the domain name www.medicure.com.

The new website has been designed to provide visitors with current and
detailed information about the Company and its initiatives in the
development of cardiovascular drugs. New features include an online
Video Gallery, featuring interviews with, among others, Medicure
President & CEO, Albert D. Friesen, Ph.D, Doctors Robert Harrington and
James Tcheng from Duke Clinical Research Institute and Dr. Yves
Lacourciere, the Principal Investigator on the MATCHED Trial.

"Our new website is an important piece of our overall Investor Relations
and Corporate Communications strategy," stated Dr. Friesen. "The Company
has made significant progress on many fronts, including both of the
Phase II clinical trials and the addition of new therapeutics to our
growing pipeline of products. The enhanced website will provide a wealth
of information about Medicure to our shareholders, strategic partners
and other members of the biotech community."

ABOUT MEDICURE INC.

Medicure Inc. is a cardiovascular drug discovery and development Company
focused on developing effective therapeutics for unmet needs in the
field of cardiovascular medicine, the largest pharmaceutical market
sector. The Company's solid position in this field is supported by the
following attributes:

- Cardiovascular focused pipeline: a global market of over US $70 billion

- Two drugs - MC-1 & MC-4232 - in advanced Phase II trials

- Two positive Phase II trials completed

- Unique products addressing major markets not adequately served by
existing drugs

- Second combination product, MC-4262 is entering development stage

- Dual action antithrombotic, MC-45308, in preclinical testing

The Company's financial position remains solid, providing sufficient
resources to complete the ongoing Phase II studies, and to advance the
lead candidates up to pivotal Phase III studies.

Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule,
anti-ischemics and anti-thrombotics towards human clinical studies.

This press release contains forward-looking statements that involve
risks, which may cause actual results to differ materially from the
statements made, and accordingly may be deemed to be forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking statements
are made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.

-30-

Contact Information